1. Home
  2. PGY vs EOLS Comparison

PGY vs EOLS Comparison

Compare PGY & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PGY
  • EOLS
  • Stock Information
  • Founded
  • PGY 2016
  • EOLS 2012
  • Country
  • PGY United States
  • EOLS United States
  • Employees
  • PGY N/A
  • EOLS N/A
  • Industry
  • PGY Finance: Consumer Services
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PGY Finance
  • EOLS Health Care
  • Exchange
  • PGY Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • PGY 707.8M
  • EOLS 702.2M
  • IPO Year
  • PGY N/A
  • EOLS 2018
  • Fundamental
  • Price
  • PGY $8.78
  • EOLS $10.51
  • Analyst Decision
  • PGY Buy
  • EOLS Strong Buy
  • Analyst Count
  • PGY 8
  • EOLS 6
  • Target Price
  • PGY $21.00
  • EOLS $22.60
  • AVG Volume (30 Days)
  • PGY 1.7M
  • EOLS 695.8K
  • Earning Date
  • PGY 02-19-2025
  • EOLS 03-06-2025
  • Dividend Yield
  • PGY N/A
  • EOLS N/A
  • EPS Growth
  • PGY N/A
  • EOLS N/A
  • EPS
  • PGY N/A
  • EOLS N/A
  • Revenue
  • PGY $970,898,000.00
  • EOLS $248,326,000.00
  • Revenue This Year
  • PGY $26.59
  • EOLS $33.43
  • Revenue Next Year
  • PGY $14.40
  • EOLS $32.44
  • P/E Ratio
  • PGY N/A
  • EOLS N/A
  • Revenue Growth
  • PGY 23.38
  • EOLS 34.42
  • 52 Week Low
  • PGY $8.20
  • EOLS $9.25
  • 52 Week High
  • PGY $20.00
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • PGY 42.09
  • EOLS 42.77
  • Support Level
  • PGY $8.27
  • EOLS $9.25
  • Resistance Level
  • PGY $9.23
  • EOLS $11.66
  • Average True Range (ATR)
  • PGY 0.63
  • EOLS 0.55
  • MACD
  • PGY -0.05
  • EOLS 0.06
  • Stochastic Oscillator
  • PGY 19.39
  • EOLS 52.28

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, big data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: